{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:45:31Z","timestamp":1787010331357,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We report a case of a 75-year-old man with concomitant metastatic prostate cancer and progressive follicular lymphoma and the utility of molecular imaging in differentiating these 2 conditions.\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT can offer accurate staging in many cancers, although its role in prostate cancer is limited. The role of\n                    <jats:sup>18<\/jats:sup>\n                    F-DCFPyL (PSMA) PET\/CT in prostate cancer is evolving and has been demonstrated to have a higher sensitivity than conventional bone scan and CT scan. Together, FDG and PSMA PET\/CT studies may offer a noninvasive approach to individually characterize concomitant malignancies, aiding optimization of management and follow-up.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000002727","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T03:06:38Z","timestamp":1564110398000},"page":"797-798","source":"Crossref","is-referenced-by-count":8,"title":["Concomitant Prostate Carcinoma and Follicular Lymphoma"],"prefix":"10.1097","volume":"44","author":[{"given":"Nattakorn","family":"Dhiantravan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hovey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annmarie","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Alina","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,7,25]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/RLU.0000000000001169","article-title":"Follicular lymphoma showing avid uptake on 68Ga PSMA-HBED-CC PET\/CT","volume":"41","year":"2016","journal-title":"Clin Nucl Med"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/RLU.0000000000001378","article-title":"Prostate-specific membrane antigen uptake is small cleaved B-cell follicular non-Hodgkin lymphoma","volume":"41","year":"2016","journal-title":"Clin Nucl Med"},{"key":"bib3-20230925","article-title":"Review of gallium-68 PSMA PET\/CT imaging in the management of prostate cancer","volume":"8","year":"2018","journal-title":"Diagnostics (Basel)"},{"key":"bib4-20230925","first-page":"668","article-title":"Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","year":"1995","journal-title":"J Nucl Med"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2967\/jnumed.117.197160","article-title":"The impact of 68Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/RLU.0b013e318252d829","article-title":"Prospective evaluation of 18F-NaF and 18F-FDG PET\/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer","volume":"37","year":"2012","journal-title":"Clin Nucl Med"},{"issue":"Suppl 4","key":"bib7-20230925","first-page":"S462","article-title":"Role of PET imaging for biochemical recurrence following primary treatment for prostate cancer","volume":"7","year":"2018","journal-title":"Transl Androl Urol"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1053\/j.semnuclmed.2016.07.004","article-title":"Is there use for FDG-PET in prostate cancer?","volume":"46","year":"2016","journal-title":"Semin Nucl Med"},{"key":"bib9-20230925","first-page":"3192","article-title":"Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature","volume":"59","year":"1999","journal-title":"Cancer Res"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T02:01:05Z","timestamp":1695607265000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002727"}},"subtitle":["\u201cFlip-Flop\u201d Appearances on PSMA and FDG PET\/CT Scans"],"short-title":[],"issued":{"date-parts":[[2019,7,25]]},"references-count":9,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002727","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,25]]}}}